t-Butyl-N-cyclohexyl-sulfonamid | 10489-82-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: t-Butyl-N-cyclohexyl-sulfonamid
• 英文别名: N-Cyclohexyl-trimethylmethan-sulfonamid；N-cyclohexyl-2-methylpropane-2-sulfonamide
• CAS: 10489-82-4
• 化学式: C₁₀H₂₁NO₂S
• 分子量: 219.348
• InChiKey: JVZHAXXNWIVANB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  叔丁基亚磺酰氯 、 N-环己基羟基胺 以 乙醚 为溶剂， 生成 t-Butyl-N-cyclohexyl-sulfonamid
  参考文献：
  名称：

  A convenient synthesis of .alkanesulfonamides

  摘要：

  DOI：

  10.1016/s0040-4039(01)84273-8

文献信息

• HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
  申请人：Incyte Corporation

  公开号：US20180009816A1

  公开（公告）日：2018-01-11

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  这种应用涉及到式（I）的化合物： 或其药用可接受的盐或立体异构体，这些化合物是PI3K-γ的抑制剂，对于治疗自身免疫疾病、癌症、心血管疾病和神经退行性疾病等疾病是有用的。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190177320A1

  公开（公告）日：2019-06-13

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物或其药学上可接受的盐：这些化合物抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，同时也作为抗病毒剂使用。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP2017261A1

  公开（公告）日：2009-01-21

  This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted lower alkyl, Y is -S(O)n- wherein n is 1 or 2, or -CO-, R2 is hydrogen or lower alkyl, R7 is hydrogen or lower alkyl, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

  本发明提供了一种式 (I) 的化合物： 其药学上可接受的盐或溶液、 其中 R1 是任选取代的低级烷基、 Y是-S(O)n- 其中n是1或2，或-CO-、 R2 是氢或低级烷基 R7 是氢或低级烷基 X 是低级烯烃、低级烯烃、芳烃、环烷烃或类似物，以及 Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物。
• COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY
  申请人：Shionogi&Co., Ltd.

  公开号：EP2280000A1

  公开（公告）日：2011-02-02

  This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

  本发明提供了一种式 (I) 的化合物： 其药学上可接受的盐或溶液、 其中 R1 是取代或未取代的烷基或类似物、 R2 是氢或取代或未取代的烷基、 环 A 是单环或双环芳香杂环，R3 是取代或未取代的芳基、取代或未取代的杂芳基或取代或未取代的杂环、 R4 是卤素、氰基、取代或未取代的烷基、取代或未取代的环烷基，或 环烷基或类似物、 m 是 0 到 2 之间的整数、 n 是 0 至 5 之间的整数、 R 是卤素、氧代、氰基、硝基、取代或未取代的烷基或类似物，以及 p 是 0 至 2 之间的整数 作为具有 NPY Y5 拮抗活性的新型化合物。
• Hepatitis B antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10428070B2

  公开（公告）日：2019-10-01

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐类： 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。